1. [The role of intraperitoneal chemotherapy after curative excision of primary abdominopelvic sarcoma].
- Author
-
Berthet B and Sugarbaker PH
- Subjects
- Abdominal Neoplasms drug therapy, Abdominal Neoplasms pathology, Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic therapeutic use, Antineoplastic Agents administration & dosage, Chemotherapy, Adjuvant, Cisplatin administration & dosage, Cisplatin therapeutic use, Disease-Free Survival, Doxorubicin administration & dosage, Doxorubicin therapeutic use, Female, Follow-Up Studies, Humans, Hyperthermia, Induced, Male, Middle Aged, Neoplasm Recurrence, Local prevention & control, Neoplasm Seeding, Pelvic Neoplasms drug therapy, Pelvic Neoplasms pathology, Prognosis, Sarcoma drug therapy, Sarcoma pathology, Survival Rate, Treatment Outcome, Abdominal Neoplasms surgery, Antineoplastic Agents therapeutic use, Chemotherapy, Cancer, Regional Perfusion, Pelvic Neoplasms surgery, Peritoneal Cavity pathology, Sarcoma surgery
- Abstract
Local recurrence and prognosis of abdominopelvic sarcomas depend on complete resection of the primary malignancy. Peritoneal seeding of the tumor can be assessed by the size of the tumor and the number of abdominopelvic regions involved by sarcoma. Under these conditions, we analyzed 14 consecutive patients with primary sarcoma. Complete resection of the tumor was performed in 9 patients with peritoneal involvement less than or equal to 3 abdomino-pelvic regions and complete resection combined with perioperative intraperitoneal chemotherapy was performed for the last 5 patient with involvement of more than 3 abdomino-pelvic regions. Results shows that the median survival was 28 months and the survival for very large tumors treated with perioperative intraperitoneal chemotherapy was similar to survival for smaller tumors treated by resection only. These results suggest the efficacy of chemotherapy on the site of resection and argue in favour of the use of regional chemotherapy in an attempt to achieve long-term disease-free survival for primary sarcoma.
- Published
- 1998